Clinical Trials Logo
  1. Home
  2. Relapse
  3. NCT04139434

Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML

Relapse Clinical Trial

Official title:
A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 as Monotherapy and in Combination With Azacitidine in Subjects With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Clinical Trial Summary

A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 as Monotherapy and in Combination with Azacitidine in Subjects with Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Clinical Trial Description

The primary objectives are to assess the safety and tolerability profile, determine the maximum tolerated dose (MTD), and/or the recommended Phase 2 dose (RP2D) of LP-108 administered daily as a single agent dosed orally and in combination with azacitidine at 75 mg/m2 in adult subjects with relapsed/refractory MDS/CMML/AML; to characterize the pharmacokinetics (PK) profile of LP-108 as monotherapy and in combination with azacitidine in adult subjects with relapsed/refractory MDS/CMML/AML. Secondary objectives are to evaluate preliminary efficacy regarding the effect of LP-108 (monotherapy or combination therapy) on ORR for AML, MDS, CMML, PFS, DOR, and OS ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04139434
Study type Interventional
Source Newave Pharmaceutical Inc
Contact
Status Active, not recruiting
Phase Phase 1
Start date July 6, 2020
Completion date January 2025
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT00306813 - Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma Phase 1/Phase 2
Completed NCT01956695 - Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma Phase 2
Not yet recruiting NCT05926167 - Observational Trial Evaluating Elevated Factor VIII Related Labs as a Biomarker for Incomplete Relapse Recovery
Recruiting NCT03710512 - Evaluation of Early Relapse After Mandibular Lengthening Surgery
Recruiting NCT04921540 - Ingrown Toenails : Surgery Only Versus Surgery + Chemical Cauterization With TCA N/A
Not yet recruiting NCT03830827 - MBRP + Vortioxetine VS MBRP on Preventing Relapse in Chronic MA Users Phase 4
Completed NCT05250765 - Comparison of Efficiency and Effectiveness of Two Types of Bonded Orthodontic Retainers: an RCT. N/A
Completed NCT05915273 - Relapse and Failure Rates Between CAD/CAM and Conventional Fixed Retainers N/A
Active, not recruiting NCT04389879 - CAD/CAM Fixed Retainers vs. Conventional Multistranded Fixed Retainers in Orthodontic Patients. Comparison of Stability, Retainer Failure Rate, Adverse Effects, Cost-effectiveness, and Patient Satisfaction. A Randomized Controlled Clinical Trial N/A
Recruiting NCT06417346 - Comparison of Laparoscopic and Open Inguinal Hernia Repair in Elderly Patients N/A
Recruiting NCT06417359 - Comparison of Mesh Fixation and Non-Fixation in eTEP N/A
Completed NCT02145403 - Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies Phase 1/Phase 2
Completed NCT01481701 - A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma Phase 2
Recruiting NCT01941394 - Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation Phase 2
Recruiting NCT04723901 - Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia Phase 1/Phase 2
Not yet recruiting NCT04994626 - Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies Phase 2
Recruiting NCT06292364 - Comparison of Retention Characteristics of Immediate vs Delayed Retainer Delivery Using 3D Digital Model Analysis N/A
Enrolling by invitation NCT05591703 - Clinical Outcomes Following Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention: A Long-term Follow-up Study
Active, not recruiting NCT00299923 - Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy Phase 3